Eli Lilly has received FDA Breakthrough Therapy designation for sofetabart mipitecan, a novel antibody-drug conjugate showing early promise for patients with platinum-resistant ovarian cancer.
Abbott has received CE Mark approval for its TactiFlex Duo Ablation Catheter in Europe, marking a major step forward in AFib treatment with dual-energy technology and successful first commercial cases.
Novavax has entered a high-value licensing deal with Pfizer, granting access to its Matrix-M adjuvant for future vaccines. The agreement brings upfront cash, milestones, and long-term royalty potential.
Sterling Hospitals, Ahmedabad, successfully performed a complex Robotic Whipple surgery, offering new hope in pancreatic cancer treatment with minimal invasiveness and faster recovery.
Moderna and Merck’s personalized skin cancer vaccine shows a 49% reduction in recurrence risk after five years, offering new hope for high-risk melanoma patients.
Novo Nordisk expands its diabetes cell therapy partnership with Aspect Biosystems, aiming to develop implantable insulin-producing cells and advance next-generation treatments for type 1 diabetes patients.
AstraZeneca has acquired AbelZeta Pharma’s remaining China rights to the CAR-T therapy C-CAR031, gaining full global control while positioning the program for broader development in liver cancer and solid tumors.
Dentalkart partners with NSK Japan to offer authentic dental equipment in India with transparent pricing and faster after-sales support.
Pfizer exits ViiV Healthcare in $1.9B deal, Shionogi doubles stake to 21.7%, while GSK retains majority, advancing long-acting HIV treatments and prevention.
GSK has agreed to acquire RAPT Therapeutics for $2.2 billion, adding ozureprubart, a long-acting anti-IgE antibody, to its pipeline and strengthening its push into food allergy treatment.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")